Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPEP: Lopinavir/ritonavir Post-Exposure Prophylaxis for COVID-19
NCT04364022Phase 3Completed
- Sponsor
- Alexandra Calmy
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lopinavir + ritonavir in coronavirus disease 2019 (COVID-19), sponsored by Alexandra Calmy. Started Apr 2020; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04364022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364022.